The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.
With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback